A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin

Exclusion Criteria

• •Are currently enrolled in, or discontinued within the last 30 days (or longer, if local guidelines require) from, a clinical trial involving an off-label use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
• •Have previously completed or withdrawn from this study or any other study investigating exenatide.
• •Have a known allergy or hypersensitivity to exenatide, sitagliptin or excipients contained in exenatide or sitagliptin.
• •Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine, or similar over-the-counter medications) within 1 month of screening.
• •Are currently treated with any of the following excluded medications:
• •* Thiazolidinediones (TZD) within 3 months of screening.
• •* Sulfonylurea (SU) within 3 months of screening.
• •* Dipeptidyl peptidase-4 \[DPP-4\] inhibitors, with the exception of sitagliptin, within 3 months of screening.
• •* Meglitinide derivatives (for example, repaglinide or nateglinide) within 3 months of screening.
• •* Alpha-glucosidase inhibitors (for example, miglitol or acarbose) within 3 months of screening.
• •* Exogenous insulin within the 3 months prior to screening.
• •* Drugs that directly affect gastrointestinal motility, including, but not limited to: metoclopramide, cisapride, and chronic macrolide antibiotics.
• •* Systemic corticosteroids (excluding topical and inhaled preparations) by oral, intravenous (IV), or intramuscular (IM) route used regularly (for longer than 1 month) or used within 1 month immediately prior to screening.
• •* Any other oral antidiabetic (OAD) agent, other than sitagliptin or metformin, within 3 months prior to screening.